Full-Life Technologies Advances FL-261 to Phase 1
London, UK, September 9, 2026 Full-Life Technologies has announced that the U.S. Food and Drug Administration (FDA) has cleared...
BioLineRx
Advertisement
BioLineRx and Hemispherian Present GLIX1 Data
Tel Aviv, Israel, and Oslo, Norway, September 10, 2026 BioLineRx Ltd. and Hemispherian AS have announced that two abstracts...
GSK Seeks EMA Approval for Bexsero Booster Vaccine Update
LONDON, United Kingdom, July 20, 2026 GSK plc has announced that the European Medicines Agency (EMA) has accepted its...
BioLineRx to Present GLIX1 Ovarian Cancer Data at ESMO 2026
TEL AVIV, Israel & OSLO, Norway, July 20, 2026 BioLineRx Ltd. and Hemispherian AS have announced that new preclinical...
BioLineRx and Hemispherian Showcase GLIX1 Cancer Data at ASCO 2026
Tel Aviv, Israel and Oslo, Norway – May 22, 2026 BioLineRx Ltd. and Hemispherian AS announced new preclinical and...
Advertisement
